Detalhe da pesquisa
1.
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
BMC Med Inform Decis Mak
; 19(1): 14, 2019 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658646
2.
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Biomark Res
; 9(1): 56, 2021 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34233760
3.
A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
PLoS One
; 16(12): e0260089, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34855780
4.
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
Oncoimmunology
; 9(1): 1773200, 2020 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923131
5.
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay.
Oncotarget
; 10(50): 5181-5193, 2019 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31497248
6.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
J Immunother Cancer
; 7(1): 27, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30709424
7.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
J Immunother Cancer
; 7(1): 18, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30678715
8.
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.
Oncoimmunology
; 7(12): e1460298, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30524881
9.
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.
J Mol Diagn
; 20(1): 95-109, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061374
10.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
J Immunother Cancer
; 6(1): 32, 2018 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29743104